ATAI Life Sciences is looking more and more like the driving force in the psychedelic drug industry.
Aion Therapeutic Files Five Patents with the United States Patent and Trademark Office
Aion Therapeutic Inc. has filed several plant-based patents with the USPTO.
TSI EDITOR |
2020-09-04
Numinus Announces Filing Final Short Form Prospectus for Offering of up to $4,000,000
Numinus seeks to raise CAD$4.0 million at an offering price of CAD$0.25 per unit.
TSI EDITOR |
2020-09-03
MagicMed Industries Closes Oversubscribed Private Placement of $1,642,880 with Mackie Research Capital Corporation
Calgary-based Magic Med Industries has raised CAD$1,642,880 from the sale of 6,571,520 shares.
TSI EDITOR |
2020-09-02
Who is Mind Cure Health?
A new functional-and-psychedelic mushroom company is preparing to go public.
TSI EDITOR |
2020-09-01
Compass Pathways Files For NASDAQ Listing: Psychedelics Game-Changer
A major IPO can be expected to attract a lot of new attention (and capital) to the psychedelic drug industry.
TSI EDITOR |
2020-08-31
Novamind Appoints Dr. Reid Robison as Chief Medical Officer
Novamind Ventures' new CMO has led over 100 clinical trials and currently serves as a Coordinating Investigator for MAPS.
TSI EDITOR |
2020-08-28
Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence
Champignon Brands advises that the BCSC has revoked its original cease trade order (June 19, 2020), but a replacement order remains in effect.
TSI EDITOR |
2020-08-27
Psychedelic Drugs Go Mainstream
As the Renaissance for psychedelic drugs progresses, we see these substances acquiring mainstream status in various ways.
TSI EDITOR |
2020-08-27
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now